Enrico Pola1, G Autore2, V M Formica3, V Pambianco2, D Colangelo2, R Cauda4, M Fantoni4. 1. Division of Spine Surgery, Department of Orthopaedics and Traumatology, "A. Gemelli" University Hospital, Catholic University of Rome, 00168, Rome, Italy. enrico.pola@tiscali.it. 2. Division of Spine Surgery, Department of Orthopaedics and Traumatology, "A. Gemelli" University Hospital, Catholic University of Rome, 00168, Rome, Italy. 3. Department of Orthopaedics and Traumatology, "Umberto I" University Hospital, La Sapienza University of Rome, 00185, Rome, Italy. 4. Department of Infectious Diseases, "A. Gemelli" University Hospital, Catholic University of Rome, 00168, Rome, Italy.
Abstract
PURPOSE: Pyogenic spondylodiscitis (PS) is still burdened by a high rate of orthopedic and neurological complications. Despite the rising incidence, the choice of a proper orthopedic treatment is often delayed by the lack of clinical data. The aim of this study was to propose a clinical-radiological classification of pyogenic spondylodiscitis to define a standard treatment algorithm. METHODS: Based on data from 250 patients treated from 2008 to 2015, a clinical-radiological classification of pyogenic spondylodiscitis was developed. According to primary classification criteria (bone destruction or segmental instability, epidural abscesses and neurological impairment), three main classes were identified. Subclasses were defined according to secondary criteria. PS without segmental instability or neurological impairment was treated conservatively. When significant bone loss or neurological impairment occurred, surgical stabilization and/or decompression were performed. All patients underwent clinical and radiological 2-year follow-up. RESULTS: Type A PS occurred in 84 patients, while 46 cases were classified as type B and 120 as type C. Average time of hospitalization was 51.94 days and overall healing rate was 92.80%. 140 patients (56.00%) were treated conservatively with average time of immobilization of 218.17 ± 9.89 days. Both VAS and SF-12 scores improved across time points in all classes. Residual chronic back pain occurred in 27 patients (10.80%). Overall observed mortality was 4.80%. CONCLUSIONS: Standardized treatment of PS is highly recommended to ensure patients a good quality of life. The proposed scheme includes all available orthopedic treatments and helps spine surgeons to significantly reduce complications and costs and to avoid overtreatment.
PURPOSE:Pyogenic spondylodiscitis (PS) is still burdened by a high rate of orthopedic and neurological complications. Despite the rising incidence, the choice of a proper orthopedic treatment is often delayed by the lack of clinical data. The aim of this study was to propose a clinical-radiological classification of pyogenic spondylodiscitis to define a standard treatment algorithm. METHODS: Based on data from 250 patients treated from 2008 to 2015, a clinical-radiological classification of pyogenic spondylodiscitis was developed. According to primary classification criteria (bone destruction or segmental instability, epidural abscesses and neurological impairment), three main classes were identified. Subclasses were defined according to secondary criteria. PS without segmental instability or neurological impairment was treated conservatively. When significant bone loss or neurological impairment occurred, surgical stabilization and/or decompression were performed. All patients underwent clinical and radiological 2-year follow-up. RESULTS: Type A PS occurred in 84 patients, while 46 cases were classified as type B and 120 as type C. Average time of hospitalization was 51.94 days and overall healing rate was 92.80%. 140 patients (56.00%) were treated conservatively with average time of immobilization of 218.17 ± 9.89 days. Both VAS and SF-12 scores improved across time points in all classes. Residual chronic back pain occurred in 27 patients (10.80%). Overall observed mortality was 4.80%. CONCLUSIONS: Standardized treatment of PS is highly recommended to ensure patients a good quality of life. The proposed scheme includes all available orthopedic treatments and helps spine surgeons to significantly reduce complications and costs and to avoid overtreatment.
Authors: Alfredo Quiñones-Hinojosa; Peter Jun; Richard Jacobs; William S Rosenberg; Philip R Weinstein Journal: Neurosurg Focus Date: 2004-12-15 Impact factor: 4.047
Authors: G S Skaf; N T Domloj; M G Fehlings; C H Bouclaous; A S Sabbagh; Z A Kanafani; S S Kanj Journal: J Infect Public Health Date: 2010-02-19 Impact factor: 3.718
Authors: Franck Grados; François Xavier Lescure; Eric Senneville; René Marc Flipo; Jean Luc Schmit; Patrice Fardellone Journal: Joint Bone Spine Date: 2007-02-02 Impact factor: 4.929
Authors: A Leone; C Dell'Atti; N Magarelli; P Colelli; A Balanika; R Casale; L Bonomo Journal: Eur Rev Med Pharmacol Sci Date: 2012-04 Impact factor: 3.507
Authors: Joseph S Butler; Martin J Shelly; Marcus Timlin; William G Powderly; John M O'Byrne Journal: Spine (Phila Pa 1976) Date: 2006-11-01 Impact factor: 3.468
Authors: Enrico Pola; F Taccari; G Autore; F Giovannenze; V Pambianco; R Cauda; G Maccauro; M Fantoni Journal: Eur Spine J Date: 2018-04-17 Impact factor: 3.134
Authors: Afonso Cardoso; Luís Barbosa; Ana Marta Coelho; João Gonçalves Correia; Hélder Larguinho Maurício; Álvaro Lima Journal: Int J Spine Surg Date: 2020-04-30